IDH1 and central nervous system cancer: Although IDH1 mutation has remained an independent favorable prognostic molecular marker for gliomas, and is more objective and reliable than clinical criteria [43, 44], all malignant gliomas with various molecular characteristics have the possibility of recurrence after operation.